Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 5/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23887886 | 0.88 | PIK3CD (0.40) | PIK3CAPIK3CDMAPK14PIK3R1PIK3CB | |
| SCHEMBL25544954 | 0.79 | MAPK14 (0.39) | PIK3CAPIK3CDMAPK14CSNK1ECSNK1D | |
| SCHEMBL25544951 | 0.75 | PDE2A (0.36) | PIK3CAPIK3CD | |
| SCHEMBL25544956 | 0.67 | TLR9 (0.35) | PIK3CD | |
| SCHEMBL23887910 | 0.66 | ALDH1A1 (0.38) | MAPK14 | |
| SCHEMBL25544357 | 0.65 | PRKDC (0.39) | MAPK14PIK3CBCSNK1ECSNK1D | |
| SCHEMBL25544752 | 0.65 | MAPK14 (0.39) | PIK3CAMAPK14PIK3CBCSNK1ECSNK1D | |
| SCHEMBL25544875 | 0.65 | TLR8 (0.39) | DYRK1A | |
| SCHEMBL23887762 | 0.64 | DYRK1A (0.40) | PIK3CAPIK3CDDYRK1A | |
| SCHEMBL25544361 | 0.63 | PDE10A (0.39) | PIK3CAPIK3CDMAPK14PIK3R1PIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | PIK3CA 4114/4885PIK3CD 3479/4885MAPK14 3750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.